Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder

Menopause

Volumn 17, Issue 4, 2010, Pages 700-711

  Soares, Claudio N ^a   Thase, Michael E ^b   Clayton, Anita ^c   Guico Pabia, Christine J ^d   Focht, Kristen ^d   Jiang, Qin ^d   Kornstein, Susan G ^e   Ninan, Phil ^d   Kane, Cecelia P ^d   Cohen, Lee S ^f  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d PFIZER INC   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Clinical trial; Depression; Desvenlafaxine; Escitalopram; Menopause

Indexed keywords

DESVENLAFAXINE; ESCITALOPRAM; CITALOPRAM; CYCLOHEXANOL DERIVATIVE; NEUROTRANSMITTER UPTAKE INHIBITOR; O-DESMETHYLVENLAFAXINE; SEROTONIN UPTAKE INHIBITOR;

ABNORMAL DREAMING; ABNORMAL THINKING; ADULT; AGED; ANXIETY; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HAMILTON SCALE; HEADACHE; HEPATITIS; HEPATOMEGALY; HUMAN; HYPERTENSION; INSOMNIA; MAJOR DEPRESSION; MENTAL INSTABILITY; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SUICIDE ATTEMPT; SWEATING; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VITAL SIGN; WITHDRAWAL SYNDROME; BLOOD PRESSURE; DEPRESSIVE DISORDER, MAJOR; LIVER FUNCTION TEST; MIDDLE AGED; SLEEP; WEIGHT GAIN;

ADULT; AGED; BLOOD PRESSURE; CITALOPRAM; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIVER FUNCTION TESTS; MIDDLE AGED; NEUROTRANSMITTER UPTAKE INHIBITORS; POSTMENOPAUSE; SEROTONIN UPTAKE INHIBITORS; SLEEP; WEIGHT GAIN;

EID: 77954952690     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181d88962     Document Type: Article

References (47)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
3. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007;370:851-858.
4. Pinto-Meza A, Usall J, Serrano-Blanco A, Suarez D, Haro JM. Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference? J Affect Disord 2006;93:53-60.
5. Thase ME, Entsuah R, Cantillon M, Kornstein SG. Relative antidepres-sant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt) 2005;14:609-616.
6. Grigoriadis S, Kennedy SH, Bagby RM. A comparison of antidepressant response in younger and older women. J Clin Psychopharmacol 2003; 23:405-407.
7. Burt VK, Wohlreich MM, Mallinckrodt CH, Detke MJ, Watkin JG, Stewart DE. Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years. Psychosomatics 2005;46:345-354.
8. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev 1999;20:279-307.
9. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry 1998;44:839-850.
10. Freeman EW, Sammel MD, Lin H, et al. Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol 2007;110:230-240.
11. Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318:657-665.
12. Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, 2008.
13. DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psy-chiatry 2007;68:677-688. (Pubitemid 46841850)
14. Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain J-M, Tourian KA. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007;22:338-347.
15. Liebowitz M, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d and 100 mg/d in outpatients with major depressive disorder. Curr Med Res Opin 2008;24:1877-1890.
16. Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolera-bility of fixed-dose desvenlafaxine 50 and 100 mg/day for major depres-sive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008;23:243-253.
17. Thase ME, Kornstein SG, Germain J-M, Jiang Q, Guico-Pabia C, Ninan PT. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr 2009;14:144-154.
18. Kornstein SG, Clayton AH, Soares CN, et al. An analysis by age and gender of efficacy data from placebo-controlled desvenlafaxine succi-nate clinical trials in depressed outpatients. Paper presented at: Annual US Psychiatric and Mental Health Congress; October 11-14, 2007; Orlando, FL.
19. Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009; CD006532.
20. Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 2009; 25:161-175.
21. Soares CN, Arsenio H, Joffe H, et al. Escitalopram versus ethinyl estra-diol and norethindrone acetate for symptomatic peri-and postmeno-pausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause 2006;13:780-786.
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychi-atry 1960;23:56-62.
23. Lexapro [package insert]. St Louis, MO: Forest Laboratories, Inc., 2009.
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th ed. Washington, DC: American Psychi-atric Association, 1994.
25. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
26. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Edu-cation, and Welfare, 1976:217-222. Publication ADM 76-338.
27. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55.
28. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573-583.
29. DeLoach LJ, Higgins MS, Caplan AB, Stiff JL. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998;86:102-106.
30. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Func-tioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull 1997;33:731-745
31. EuroQolVa new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
32. Heinemann K, Ruebig A, Potthoff P, et al. The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes 2004;2:45.
33. Sheehan DV. Sheehan Disability Scale. In: Rush AJ, Pincus HA, First MB, et al, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association, 2000:113-115.
34. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG. Quantita-tive rating of depressive states. Acta Psychiatr Scand 1975;51:161-170.
35. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998;44:77-87.
36. Brown H, Prescott R. Applied Mixed Models in Medicine. Chichester, PA: John Wiley & Sons, 1999.
37. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry 2006;63:385-390.
38. Soares CN. Depression during menopausal transition: window of vul-nerability of continuum of risk? Menopause 2008;15:207-209.
39. Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of peri-and postmenopausal women with major depressive disorder. Manuscript in preparation.
40. Gartlehner G, Hansen RA, Carey TS, Lohr KN, Gaynes BN, Randolph LC. Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis. Int Clin Psychopharmacol 2005;20:59-69.
41. Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008;63:424-434.
42. Guo SS, Zeller C, Chumlea WC, Siervogel RM. Aging, body composi-tion, and lifestyle: the Fels Longitudinal Study. Am J Clin Nutr 1999;70: 405-411.
43. Clayton AH, Kornstein SG, Rosas G, Guico-Pabia C, Tourian KA. An integrated analysis of the safety and tolerability of desvenlafaxine com-pared with placebo in the treatment of major depressive disorder. CNS Spectr 2009;14:183-195.
44. Siddiqui O, Hung HM, O'Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat 2009;19:227-246.
45. Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 2009;31:1405-1423.
46. Molenberghs G, Thijs H, Jansen I, et al. Analyzing incomplete longi-tudinal clinical trial data. Biostatistics 2004;5:445-464.
47. Mallinckrodt CH, Kaiser CJ, Watkin JG, Molenberghs G, Carroll RJ. The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA. Clin Trials 2004;1:477-489.